Apps in this category may contain mild or occasional cartoon, fantasy or real-life violence, as well as occasional or mild adult, sexually suggestive or horrifying content and may not be suitable for children under 9 years of age.

12+

Apps in this category may contain occasional mild indecent language, frequent or intense cartoon or real-life violence, minor or occasional adult or sexually suggestive material, and simulated gambling, and may be for children under 12 years of age.

17+

You must be at least 17 years old to access this App.

Apps in this category may contain frequent and intense offensive language; Frequent and intense cartoon, fantasy or realistic violence: frequent and intense adult, scary and sexually suggestive subjects: as well as sexual content, nudity, tobacco, alcohol and drugs, may not be suitable for children under 17 years of age.

AntiCoagAF 螢幕截圖

iPad

iPhone

About AntiCoagAF

This application is for medical practitioners who need to quickly review which anticoagulant (including the direct oral anticoagulants (DOACs)) to use to prevent stroke in patients with non-valvular atrial fibrillation (NVAF).

It contains relevant information about warfarin, apixaban, dabigatran, rivaroxaban and edoxaban.

Topics covered include: comparison of anticoagulants, patient information, when anticoagulation is required, risk-benefit issues, when warfarin is appropriate, how to choose the dose of a DOAC, starting or switching between anticoagulants, edoxban information, clinical monitoring, bleeding risks, use of antiplatelet agents in addition to oral anticoagulants, managing ischemic strokes on DOACs, reversing anticoagulation in the event of intracerebral haemorrhage, a Cookcroft-Gault creatinine clearance calculator and peri-operative management information.

Information contained within the application was edited by Dr Bruce Campbell. Coding was by CereScape (www.cerescape.com). It is our aim to keep this information current, and we welcome constructive comments and evidenced updated information. Any profit generated by this application will be used to fund stroke research.